Stoke Therapeutics Signs Lease for New 98,500-Square-Foot Headquarters in Waltham
Reuters
Jan 28
Stoke <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Signs Lease for New 98,500-<a href="https://laohu8.com/S/XYZ">Square</a>-Foot Headquarters in Waltham
Stoke Therapeutics Inc. has announced plans to relocate its headquarters to a new 98,500 square-foot facility at 245 Fifth Avenue in Waltham, Massachusetts. The move, set for late 2026 when the company’s current Bedford lease ends, will support Stoke’s efforts to commercialize its lead medicine, zorevunersen, for Dravet syndrome and expand research activities.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stoke Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE72225) on January 27, 2026, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.